Heart Test Laboratories, Inc.

NasdaqCM HSCS

Heart Test Laboratories, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.42

Heart Test Laboratories, Inc. Price to Earnings Ratio (P/E) is -0.42 on January 14, 2025, a 70.41% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Heart Test Laboratories, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.00 on December 13, 2024, which is 99.58% above the current Price to Earnings Ratio (P/E).
Heart Test Laboratories, Inc. 52-week low Price to Earnings Ratio (P/E) is -2.22 on March 05, 2024, which is -428.27% below the current Price to Earnings Ratio (P/E).
Heart Test Laboratories, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.81.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: HSCS

Heart Test Laboratories, Inc.

CEO	Mr. Andrew Simpson
IPO Date	June 16, 2022
Location	United States
Headquarters	550 Reserve Street
Employees	15
Sector	Health Care
Industries Medical Instruments Telehealth

Description

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key trends

Past 5 years